Wohua Medicine has a deficit of nearly billion this year.

Because the leading product heart can not enter the National basic Drug catalogue, Wohua Medicine (002107) today disclosed three quarterly data dismal. Three quarterly reports show that Wohua medicine in the third quarter to achieve total operating income of 14.5986 million yuan, down 0.9% year-on-year, to achieve net profit-29.0903 million yuan.　　Wohua Pharma is expected to lose 9.5001 trillion of its 2010 earnings. Wohua Medicine said, because the company's leading products have not entered the 2009 "National Basic Medicine record (primary medical and health structure supporting use part)", in this year's provincial Drug Administration in the unified procurement of tenders failed to enter the list of tenders, The county and the following community medical institutions on which they are selling have seen a sustained and steep decline since the beginning of the year. As a result, the medical institutions to the commercial companies to return slowly, making it difficult for commercial companies to timely Wohua medicine back.　　According to the Wohua medicine accounts receivable bad debt extraction policy, the company carries out a separate impairment test for individual significant accounts receivable and extracts the bad debts preparation. Affected by this, Wohua medicine 1-9-month business receipts fell 50.6% from the same period last year, asset impairment losses from the same period increased by 21.1955 million yuan, the end of the net accounts receivable than the beginning of the reduction of 24.2731 million yuan. At the same time, Wohua pharmaceutical sales in January-September compared with the same period last year increased by 38.37%, mainly due to the company to curb the declining sales revenue, increase the investment in sales costs, and continuously expand the marketing network.